Leading Element Driving Change in the Venous Thromboembolism Market in 2025: Impact Of Healthcare Infrastructure Expansion On The Venous Thromboembolism Market Driver

What combination of drivers is leading to accelerated growth in the venous thromboembolism market?
The enhancement of healthcare facilities is seen as a primary factor that will boost the growth of the venous thromboembolism sector in the future. The term "healthcare industry" refers to the merging and intermingling of different segments within the economic framework that produce and provide services and products for treating patients, prevention of diseases, rehabilitation, along with palliative care. With the growth and development of the healthcare sector comes the expansion of necessary institutional infrastructures, policies, practices, and educational programs essential for the execution of VTE prevention measures. To illustrate, the American Health Care Association, a nonprofit organization based in the U.S., stated that the count of hospitals in the US rose from 6,093 in 2022 to 6,129 in May 2023. At the same time, the Office for National Statistics in the UK declared in May 2023, that healthcare expenditure for the year 2023 was £292 billion, showing a nominal increase of 5.6%. Likewise, the expenditure on long-term health and social care went up by 2.8% in real terms in 2022. Hence, the growth of the healthcare sector is one of the significant factors steering the expansion of the venous thromboembolism market. Further, it is anticipated that the increasing instances of orthopedic procedures will spur the increase of the venous thromboembolism market in the future. These procedures are surgeries performed to correct issues related to the spine, joints, and skeletal deformities. Orthopedic procedures like total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS) come with a high VTE risk. This has resulted in a higher usage of compression devices for DVT prophylaxis, which helps avoid the formation of blood clots in deep leg veins, potentially leading to venous thromboembolism (VTE). A case in point would be a study shared by the National Library of Medicine (a biomedical library based in the U.S.) in February 2023. According to it, the number of THA and TKA procedures will reach figures of 719,364 and 1,222,988 respectively by 2040. Further, by 2060, the number of TKA procedures is expected to reach 2,917,959, with THAs projected to reach 1,982,099. Therefore, the increase in orthopedic operations is another key driver of growth in the venous thromboembolism market.

Get Your Venous Thromboembolism Market Report Here:
https://www.thebusinessresearchcompany.com/report/venous-thromboembolism-global-market-report

What is the projected compound annual growth rate (CAGR) of the venous thromboembolism market from 2025 to 2034, and what factors influence it?
In the past few years, there's been a stable increase in the size of the venous thromboembolism market. The market value is projected to rise from $2.44 billion in 2024 to $2.55 billion in 2025, with a compound annual growth rate (CAGR) of 4.4%. The growth experienced in the historic period can be linked to factors such as an aging population, developments in anticoagulants, reimbursement strategies, and an upsurge in investments.

In the upcoming years, a consistent growth is anticipated for the venous thromboembolism market. It is projected to expand to a value of $3.02 billion by 2029, with a compound annual growth rate (CAGR) of 4.4%. The factors fuelling this growth during the forecast period include advancements in global healthcare access, genetic risk evaluation, telemedicine and remote monitoring technology, as well as patient education and support systems. The forecast period is also expected to witness significant trends such as the increased use of extended thromboprophylaxis, new oral anticoagulants, personalized treatment approaches, and enhanced diagnostic imaging techniques.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13001&type=smp

How are the latest trends influencing the growth of the venous thromboembolism market?
Key enterprises in the venous thromboembolism market are advancing their stance by creating innovative anti-clotting medications and solutions. Their progressive developments have the potential to yield highly effective drugs that can treat or mitigate venous thromboembolism. A case in point is the regulatory green light received by Anthos Therapeutics in September 2022 from the US Food and Drug Administration (FDA) for its groundbreaking anticoagulant, abelacimab. This Boston-based biotherapeutics firm developed this fully human monoclonal antibody to provide prevention against stroke and systemic embolism in atrial fibrillation patients. Abelacimab, a unique, dual-action antibody administered once a month, aims to enable the process of clot-stopping anticoagulation, through the inhibition of Factor XI.

What are the major segments of the venous thromboembolism market and their role in driving growth?
The venous thromboembolism market covered in this report is segmented -

1) By Type: Deep Vein Thrombosis, Pulmonary Embolism, Other Types
2) By Treatment: Anti-Clotting Medications, Mechanical Devices, Thrombolytic Therapy, Other Treatment
3) By End Users: Hospitals, Homecare, Specialty Centers, Other End Users

Subsegments:
1) By Deep Vein Thrombosis (DVT): Proximal DVT, Distal DVT, Asymptomatic DVT
2) By Pulmonary Embolism (PE): Acute PE, Chronic PE, Submassive PE
3) By Other Types: Thrombophlebitis, Superficial Vein Thrombosis, Post-Thrombotic Syndrome

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13001

North America was the largest region in the venous thromboembolism market in 2024. The regions covered in venous thromboembolism market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the key firms paving the way for growth in the venous thromboembolism market?
Major companies operating in the venous thromboembolism market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Endo International PLC, Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd., LEO Pharma A/S, Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Glenmark Pharmaceuticals Ltd., Portola Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13001&type=smp

What Is Covered In The Venous Thromboembolism Global Market Report?

•Market Size Forecast: Examine the venous thromboembolism market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the venous thromboembolism market for a structured understanding.
•Key Players Overview: Analyze major players in the venous thromboembolism market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the venous thromboembolism market.
•Segment Contributions: Evaluate how different segments drive overall growth in the venous thromboembolism market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the venous thromboembolism market.
•Industry Challenges: Identify potential risks and obstacles affecting the venous thromboembolism market.
•Competitive Landscape: Review strategic developments in the venous thromboembolism market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.